OS Therapies Incorporated - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
OSTX NYSE American 2834 ostherapies.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for OS Therapies Incorporated

OS Therapies Enters into Warrant Inducement Agreements - Jan 12th, 2026 6:01 am
OS Therapies Provides First Half 2026 Corporate Outlook - Jan 5th, 2026 5:40 am
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Dec 15th, 2025 4:00 am
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Dec 9th, 2025 5:40 am
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility - Dec 5th, 2025 6:01 am
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization - Nov 25th, 2025 7:21 am
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25 - Nov 21st, 2025 2:15 pm
OS Therapies to Spinoff OS Animal Health into Standalone Public Company - Nov 20th, 2025 5:40 am
OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 17th, 2025 4:00 am
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Oct 22nd, 2025 7:15 am
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Oct 17th, 2025 7:15 am
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma - Oct 10th, 2025 4:00 am
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting - Oct 9th, 2025 5:40 am
OS Therapies to Participate in Fall 2025 Conferences and Events - Oct 7th, 2025 9:50 am
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update - Sep 30th, 2025 5:40 am
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT - Sep 19th, 2025 5:40 am
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit - Sep 12th, 2025 5:40 am
Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX) - Sep 8th, 2025 3:13 pm
OS Therapies to Participate in Upcoming Investor Conferences in September 2025 - Sep 3rd, 2025 5:40 am
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting - Sep 2nd, 2025 5:40 am